Aldeyra Therapeutics (ALDX) stock
Follow ALDX's trial news. Pro members can get an alert when Aldeyra Therapeutics files news, and see its trials, share raises, and its CEO's filings.
What's next for ALDX, and how long its cash lasts
From Aldeyra Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
The company says its cash lasts into 2029 (8-K, Sep 29).
Dilution on the horizon
- Shelf registration (S-3, filed Mar 7, 2024)
- At-the-market share sales program (424B5, filed Aug 1, 2024)
Insiders
CEO Todd C Brady bought 250,000 shares on Jun 3. 2 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 28 daysINOInovio Pharmaceuticals
INOINO-3107
- In 39 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 51 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why it's down
Down 49% in 3 months, 17% under its 50-day average.
Down more than its industry: the 275 other stocks in it fell a median 11% over the same 3 months.
−3Long-term trend below a falling 200-day average, down over one year, down over two years
3 more things pulling ALDX's score down, for Pro members
What's next
Expected to report Wed Nov 4, after the close
What would turn ALDX's score around: 7 things, for Pro members
Here is what Pro members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
ALDX has 1 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1443.6
- MACD (12, 26, 9)Below signal
- 50-day average$1.47
- 200-day average$2.69
- ADX 1425.2
- Support$1.07
- Resistance$1.55
- Bollinger Bands (20, 2)Inside
- Volume1.2x
How ALDX ranks in Biotech
ALDX is #220 of 276 by Quality Score. The top three are shown with their scores, and more by name.
KNSA7/1418
ABCL6/1416
OABI9/1415
ADPTOpen for its score
AGIOOpen for its score
ALNYOpen for its score
ALTOpen for its score
ALDX1/14-5
When does ALDX report earnings, and what happens after?
Expected to report Wed Nov 4, after the close (in 33 days). Not yet confirmed by the company.
Who is trading ALDX
ALDX insider trades
One insider bought $418K across 1 filing in the last 6 months. No open-market sales on record. The newest:
About Aldeyra Therapeutics
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of ALDX's score, with the points and the reason
- All 14 checks on ALDX and on all 2,958 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on ALDX
Straight Answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.